Compugen Ltd. company was founded in 1993 and is based in Tel Aviv, Israel. Compugen Ltd. (Compugen) is engaged in drug and diagnostic product candidate discovery and the commercialization of such candidates through early-stage licensing and co-development agreements. The Company’s business is focused on developing and using predictive computer-based discovery platforms to discover therapeutic drug candidates and diagnostic biomarker candidates. The Company uses experimental biological processes to validate product candidates discovered by its predictive platforms. Its initial discovery platforms focused mainly on cancer, cardiovascular and immune-related diseases. In July 2008, Compugen announced results from an in vivo study of CGEN-25007, a peptide antagonist of the gp96 protein. The data indicate that CGEN-25007 has immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.

Marshall Edwards, Inc. was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited. Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol.

Pharmavite's Nature Made brand of vitamins, mineral supplements, and herbal remedies are sold through major mass retailers and drugstore chains. Like all successful supplement makers, Pharmavite's product lines shift and adapt and new product development is key. It has entered the snack food segment with its SOYJOY nutrition bars and manufactures vitamins under the Olay brand. Pharmavite was founded in 1971 and acquired by Otsuka Pharmaceutical in 1989. Otsuka has since introduced the Nature Made vitamin brand to Japan. Pharmavite manufactures all of its products at its facilities in California.

Bluebonnet, which manufactures the majority of its products at its facility in Texas, was founded in 1991. Bluebonnet Nutrition Corp. makes and markets vitamins and other dietary supplements, including amino acids and herbs, under the Bluebonnet brand name. It provides its supplements in multiple forms, such as capsules, soft gels, powders, and liquids. Lead products include Super Earth Phytonutrient Soy Protein Powder and Multi-Action Whey of Life Protein Powder. The family-owned company sells its products in health and natural food stores throughout the US, as well as in Europe and Asia, to retailers that include Whole Foods Market.

Mikart offers contract pharmaceutical manufacturing services, specializing in oral capsule and tablet formulations. Tablets and capsules can be immediate or time-release; the company also makes liquid formulations and provides specialty packaging, including laminated foil, blister, and pouches. Its facilities have the capacity to produce everything from small pilot-scale batches all the way up to full-scale commercial production. Other services include drug development, feasibility studies, and product testing. Mikart will also walk customers through all the required regulatory processes.

Cangene Corporation company makes plasma products known as hyperimmunes, which are antibody preparations and recombinant biopharmaceuticals made by introducing a gene in a host organism. Cangene's drugs are used to treat plasma-derived disorders, including the blood clotting disorder thrombocytopenic purpura and hemolytic disease of the newborn, which occurs when a fetus' blood type is incompatible with its mother's. Cangene has several approved products and is developing others, mainly in the areas of infectious disease and biodefense. Generic giant Apotex owns more than 80% of Cangene.

Sanofi-Aventis Deutschland boasts itself as one of the largest pharmaceutical businesses in the country. A subsidiary of French giant Sanofi-Aventis, the company manufactures and markets prescription and over-the-counter drugs. Along with its Lantus and Insuman insulin products, Sanofi-Aventis Deutschland produces Plavix and Lovenox. The company also dedicates much of its efforts on research and development at its Frankfurt, Germany headquarters and is focused on metabolic illnesses such as diabetes, as well as cancer and cardiovascular diseases.

Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical company with a focus on cardiovascular disease. Amarin has a range of clinical and preclinical stage compounds to treat central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease. Its cardiovascular programs and non-core CNS programs include AMR101, EN101, Sublingual Apomorphine and AMR 103. The Company's subsidiaries include Amarin Neuroscience Limited, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc, Amarin Finance Limited and Ester Neurosciences Limited.

China Shineway Pharmaceutical Group Limited company develops, manufactures, and sells modern Chinese medicines and western pharmaceuticals. Three of its principal products are Xin Nao Qing soft capsules, Qingkailing injection, and Shenmai injection -- the company's production of these three products is the largest in China. Shineway has plans to expand its sales and marketing network, focusing on hospitals and retail pharmacies to expand its market coverage and deepen its market penetration. Chairman Li Zhenjiang and his family control more than 70% of the company.

Futura Medical plc company, which develops pharmaceutical and other medical products for sexual dysfunctions in both men and women, uses the DermaSys technology in its MED2002 non-prescription topical gel being developed with GlaxoSmithKline as an erectile dysfunction product. Futura is exploring other applications for DermaSys as MED2002 continues clinical trials. Other products include CSD500, a device to reduce condom slippage, and FLD 500, the company's Female Lubrication Device that is globally marketed and distributed by SSL International.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.